Itch in Scabies-What Do We Know?

被引：12
|
作者：
Staender, Sascha [1 ]
Staender, Sonja [2 ]
机构：
[1] Univ Lubeck, Dept Dermatol, Lubeck, Germany
[2] Univ Hosp Munster, Ctr Chron Pruritus, Dept Dermatol, Munster, Germany
来源：
FRONTIERS IN MEDICINE | 2021年 / 8卷
关键词：
scabies; itch; pruritus; itch mediators; itch and its pathways; NOCTURNAL PRURITUS; SARCOPTES-SCABIEI; ATOPIC-DERMATITIS; GLOBAL BURDEN; MITE; PREVALENCE; INHIBITORS; PSORIASIS; EPIDEMIC; IMPETIGO;
D O I：
10.3389/fmed.2021.628392
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Scabies is a common parasitic skin infestation characterized by severe itch and a heterogenous clinical presentation. Itch, as the cardinal symptom of scabies, is imposing a high burden on affected patients and is often difficult to manage. Decreased life quality and secondary complications, caused by an itch-related disruption of the epidermal barrier and subsequent superinfections, illustrate the need to treat scabies and to understand the underlying mechanisms of itch in respective patients. This review summarizes available data on itch in scabies with a special focus on the clinical aspects and its underlying pathomechanisms.
引用
收藏
页数：6
相关论文
共 50 条
  • [41] Probiotics for Childhood Functional Gastrointestinal Disorders: Do We Know What We Advise?
    Browne, P. D.
    de Groen, A. C.
    Claassen, E.
    Benninga, M. A.
    PHARMANUTRITION, 2019, 10
  • [42] Pneumonia in Bhutanese children: what we know, and what we need to know
    Jullien, Sophie
    Pradhan, Dinesh
    Bassat, Quique
    PNEUMONIA, 2020, 12 (01)
  • [43] Skin Barrier in Normal and Allergic Horses: What Do We Know?
    Marsella, Rosanna
    VETERINARY SCIENCES, 2025, 12 (02)
  • [44] Cancer drugs for hepatitis B treatment: what do we know?
    Ebert, Gregor
    Pellegrini, Marc
    FUTURE VIROLOGY, 2015, 10 (09) : 1025 - 1028
  • [45] The biology of chikungunya: A brief review of what we still do not know
    Pardigon, N.
    PATHOLOGIE BIOLOGIE, 2009, 57 (02): : 127 - 132
  • [46] Total Knee Arthroplasty in Patients with Hemophilia: What Do We Know?
    Mortazavi, S. M. Javad
    Bagheri, Nima
    Farhoud, Amirreza
    Kalantar, Saeid Hadi
    Ghadimi, Ehsan
    ARCHIVES OF BONE AND JOINT SURGERY-ABJS, 2020, 8 (04): : 470 - 478
  • [47] Fibromuscular dysplasia of the renal arteries: what do we know in 2024?
    Tournebize, Corentin
    Lemoine, Sandrine
    Pelletier, Caroline
    NEPHROLOGIE & THERAPEUTIQUE, 2024, 20 (02): : 131 - 139
  • [48] Hepatitis E Virus: What More Do We Need to Know?
    Shahini, Endrit
    Argentiero, Antonella
    Andriano, Alessandro
    Losito, Francesco
    Maida, Marcello
    Facciorusso, Antonio
    Cozzolongo, Raffaele
    Villa, Erica
    MEDICINA-LITHUANIA, 2024, 60 (06):
  • [49] Venous thromboembolism in palliative care patients: what do we know?
    Noble, Simon
    THROMBOSIS RESEARCH, 2020, 191 : S128 - S132
  • [50] The Weight of Vitamin D on Obesity Outcomes: What Do We Know?
    Bialo, Shara R.
    Gordon, Catherine M.
    JOURNAL OF ADOLESCENT HEALTH, 2015, 57 (01) : 1 - 2
12345